Palisade Bio Yönetim
Yönetim kriter kontrolleri 1/4
Palisade Bio's CEO is J. Finley, appointed in Apr 2021, has a tenure of 3.58 years. total yearly compensation is $1.28M, comprised of 40.7% salary and 59.3% bonuses, including company stock and options. directly owns 1.14% of the company’s shares, worth $37.32K. The average tenure of the management team and the board of directors is 2.4 years and 0.8 years respectively.
Anahtar bilgiler
J. Finley
İcra Kurulu Başkanı
US$1.3m
Toplam tazminat
| CEO maaş yüzdesi | 40.7% |
| CEO görev süresi | 3.6yrs |
| CEO sahipliği | 1.1% |
| Yönetim ortalama görev süresi | 2.4yrs |
| Yönetim Kurulu ortalama görev süresi | less than a year |
Son yönetim güncellemeleri
Recent updates
Palisade Bio announces CEO transition
Oct 11Palisade Bio streamlines operations, including cutting 20% of employees
Sep 15Palisade Bio GAAP EPS of -$0.12
Aug 15Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function
Jul 27Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy
Jun 29Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely
Mar 28
Palisade Bio: Guarding Intestinal Integrity
Nov 07CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$14m |
| Mar 31 2024 | n/a | n/a | -US$14m |
| Dec 31 2023 | US$1m | US$520k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$13m |
| Jun 30 2023 | n/a | n/a | -US$14m |
| Mar 31 2023 | n/a | n/a | -US$13m |
| Dec 31 2022 | US$614k | US$441k | -US$15m |
| Sep 30 2022 | n/a | n/a | -US$9m |
| Jun 30 2022 | n/a | n/a | -US$358k |
| Mar 31 2022 | n/a | n/a | -US$27m |
| Dec 31 2021 | US$1m | US$365k | -US$27m |
| Sep 30 2021 | n/a | n/a | -US$32m |
| Jun 30 2021 | n/a | n/a | -US$39m |
| Mar 31 2021 | n/a | n/a | -US$12m |
| Dec 31 2020 | US$532k | US$293k | -US$10m |
Tazminat ve Piyasa: J.'s total compensation ($USD1.28M) is above average for companies of similar size in the US market ($USD655.65K).
Tazminat ve Kazançlar: J.'s compensation has increased whilst the company is unprofitable.
CEO
J. Finley (67 yo)
3.6yrs
Görev süresi
US$1,277,100
Tazminat
Mr. J. D. Finley serves as its Chief Executive Officer of Palisade Bio, Inc. since 2023 and has been its Director since February 2023. He serves as the Chief Financial Officer at Palisade Bio, Inc. (Altern...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, CFO & Director | 3.6yrs | US$1.28m | 1.14% $ 37.3k | |
| COO & Chief Medical Officer | 1.2yrs | US$738.81k | 0.33% $ 10.7k | |
| Head of Translational Science & Medicine | less than a year | Veri yok | Veri yok | |
| Senior VP of Finance & Corporate Controller | 6.4yrs | Veri yok | Veri yok |
2.4yrs
Ortalama Görev Süresi
Deneyimli Yönetim: PALI's management team is considered experienced (2.4 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, CFO & Director | 1.8yrs | US$1.28m | 1.14% $ 37.3k | |
| Independent Director | less than a year | Veri yok | Veri yok | |
| Independent Chairman of the Board | 3.6yrs | US$87.23k | 0.28% $ 9.3k | |
| Member of Clinical Advisory Board | less than a year | Veri yok | Veri yok | |
| Member of Clinical Advisory Board | less than a year | Veri yok | Veri yok |
0.8yrs
Ortalama Görev Süresi
67yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: PALI's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.